About Renovaro
Renovaro is a company based in Los Angeles (United States) founded in 2023. It operates as a AI-as-a-Service and Professional Services. Renovaro has completed 1 acquisition, including Predictive Oncology. Renovaro offers products and services including AI Drug Discovery Platform, Precision Medicine Solutions, and Augusta Platform.
- Headquarter Los Angeles, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Renovaro
Renovaro offers a comprehensive portfolio of products and services, including AI Drug Discovery Platform, Precision Medicine Solutions, and Augusta Platform.
AI platform used for biomarker discovery in cancer.
Solutions tailored for personalized cancer treatment strategies.
Platform developed for neurological disease diagnosis support.
Funding Insights of Renovaro
Detailed funding history for Renovaro
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Renovaro
Renovaro has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Predictive Oncology.
Investment portfolio details for Renovaro
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AI-based platform for cancer diagnostics and precision medicine is utilized.
|
Locked | Locked | 2002 | Locked |
Complete acquisition details for Renovaro
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Renovaro
Detailed financials for Renovaro
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Renovaro Comparisons
Peer comparison for Renovaro
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Renovaro
Detailed competitors of Renovaro
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Renovaro
Complete news archive for Renovaro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Renovaro
Renovaro was founded in 2023.
Renovaro is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Renovaro is engaged in leveraging AI technology for cancer diagnostics and precision medicine. The company operates in the healthcare and biotechnology sectors, offering solutions for biomarker discovery, early disease detection, and personalized treatments. Through its full-stack Bio-AI platform, Renovaro supports clinicians in improving patient outcomes across cancer and neurology care. Key initiatives include AI drug discovery, predictive analytics, and therapeutic development for specific genetic profiles. Strategic mergers and grants, such as with GEDiCube and BioSymetrics, enhance its capabilities in minimal residual disease detection and neurological diagnostics.
Renovaro offers AI Drug Discovery Platform, Precision Medicine Solutions, and Augusta Platform.
Renovaro has made 1 acquisition, including Predictive Oncology.